A significant accomplishment for the Valneva chikungunya vaccine as FDA considers its application
A single-dose, live-attenuated vaccine candidate called VLA1553 is being developed to combat the extremely risky chikungunya virus. The US Food and Drug Administration (FDA) is now assessing Valneva’s biologics licensing application for its single-shot chikungunya vaccine candidate.